CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
Shares of Innovate Corp. (NYSE:VATE) surged 60% following the announcement that the U.S. Food and Drug Administration (FDA) ...
CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...